-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since January, institutional research has remained popular.
In the field of medicine and biology, Mindray Medical and Jiu'an Medical have received intensive research from more than 100 institutions, and Mindray Medical has received research from 430 institutions within a week
.
Mindray Medical: Surveyed by 430 Institutions Mindray Medical is a domestic medical device giant and solution provider.
The company's products cover three categories of life information and support, in vitro diagnosis and medical imaging systems
.
According to the investor relations activity record sheet released by the company on January 17, from January 4 to January 7, January 10 to January 14, and January 17, 2022, the company received a total of 430 institutions 742 participants
.
During the research activities, the agency paid attention to the completion of the inspection production line of the company's Shanghai branch, the current progress of the new domestic medical infrastructure and continued expectations in the future, the company's blockbuster product "Sanrui" ecology, and hospital admissions in 2021.
situation, company highlights in 2022,
etc.
Among the highlights of the company in 2022, Mindray Medical said that in 2022, the company expects that its main business will maintain steady growth, and its emerging business will continue to develop rapidly
.
Specifically, there are four important directions worthy of attention, including: the growth of the in vitro diagnostic business will accelerate; the company will continue to support the new medical infrastructure on a global scale, continue to achieve breakthroughs in high-end hospitals and increase the penetration rate, and expand brand influence; orthopedics and Some IVD products have benefited from the influence of centralized procurement, DRGS and other policies in some regions, and the market coverage and share have been accelerated.
Accelerate the launch of new products and continue to achieve rapid growth
.
It is worth mentioning that Mindray Medical is also a company favored by research institutions in 2021.
According to industry statistics, Mindray Medical will have a total of 3,040 surveys in 2021, and there will be 1,553 research institutions
.
From the perspective of stock price growth, Mindray Medical hit a high of 502 yuan in July 2021, and then the stock price began to fall.
In less than two months, the stock price fell by more than 40%.
.
Entering 2022, the draft employee stock ownership plan was introduced, and the stock price trend, which had been declining since the beginning of the month, was changed
.
As of the close on January 21, Mindray Medical's share price was at 342.
22 yuan, with a market value of 416 billion yuan
.
Jiu'an Medical: Over 100 Institutions Investigated Jiu'an Medical, which has been continuously increasing its daily limit recently, has also been investigated by over 100 institutions
.
Since mid-November 2021, in a total of 44 trading days, Jiu'an Medical has gained 27 daily limit prices, rising from less than 7 yuan per share to the closing price of over 75 yuan, a cumulative increase of more than 1000%
.
According to the information disclosed by the Shenzhen Stock Exchange, on January 14, more than 100 institutions conducted a teleconference to investigate Jiu'an Medical.
The participating units included Essence Securities, Caitong Securities, Dongcai Fund, and Wells Fargo Fund
.
During the question-and-answer session of the meeting, the organization paid great attention to the company's production capacity planning and post-work arrangements, and whether the products have a price increase plan and many other issues
.
Among them, in terms of production capacity specifications, the company said that China has manufacturing capacity and labor resources.
In terms of raw material supply, the domestic industrial chain has the ability to supply raw materials after exporting European kits last year.
The increase in production capacity mainly depends on the supply of labor and labor, but There is a time course for productivity improvement
.
The company will comprehensively consider the two factors of efficiency and risk, and rationally plan production-related arrangements
.
In the field of medicine and biology, Mindray Medical and Jiu'an Medical have received intensive research from more than 100 institutions, and Mindray Medical has received research from 430 institutions within a week
.
Mindray Medical: Surveyed by 430 Institutions Mindray Medical is a domestic medical device giant and solution provider.
The company's products cover three categories of life information and support, in vitro diagnosis and medical imaging systems
.
According to the investor relations activity record sheet released by the company on January 17, from January 4 to January 7, January 10 to January 14, and January 17, 2022, the company received a total of 430 institutions 742 participants
.
During the research activities, the agency paid attention to the completion of the inspection production line of the company's Shanghai branch, the current progress of the new domestic medical infrastructure and continued expectations in the future, the company's blockbuster product "Sanrui" ecology, and hospital admissions in 2021.
situation, company highlights in 2022,
etc.
Among the highlights of the company in 2022, Mindray Medical said that in 2022, the company expects that its main business will maintain steady growth, and its emerging business will continue to develop rapidly
.
Specifically, there are four important directions worthy of attention, including: the growth of the in vitro diagnostic business will accelerate; the company will continue to support the new medical infrastructure on a global scale, continue to achieve breakthroughs in high-end hospitals and increase the penetration rate, and expand brand influence; orthopedics and Some IVD products have benefited from the influence of centralized procurement, DRGS and other policies in some regions, and the market coverage and share have been accelerated.
Accelerate the launch of new products and continue to achieve rapid growth
.
It is worth mentioning that Mindray Medical is also a company favored by research institutions in 2021.
According to industry statistics, Mindray Medical will have a total of 3,040 surveys in 2021, and there will be 1,553 research institutions
.
From the perspective of stock price growth, Mindray Medical hit a high of 502 yuan in July 2021, and then the stock price began to fall.
In less than two months, the stock price fell by more than 40%.
.
Entering 2022, the draft employee stock ownership plan was introduced, and the stock price trend, which had been declining since the beginning of the month, was changed
.
As of the close on January 21, Mindray Medical's share price was at 342.
22 yuan, with a market value of 416 billion yuan
.
Jiu'an Medical: Over 100 Institutions Investigated Jiu'an Medical, which has been continuously increasing its daily limit recently, has also been investigated by over 100 institutions
.
Since mid-November 2021, in a total of 44 trading days, Jiu'an Medical has gained 27 daily limit prices, rising from less than 7 yuan per share to the closing price of over 75 yuan, a cumulative increase of more than 1000%
.
According to the information disclosed by the Shenzhen Stock Exchange, on January 14, more than 100 institutions conducted a teleconference to investigate Jiu'an Medical.
The participating units included Essence Securities, Caitong Securities, Dongcai Fund, and Wells Fargo Fund
.
During the question-and-answer session of the meeting, the organization paid great attention to the company's production capacity planning and post-work arrangements, and whether the products have a price increase plan and many other issues
.
Among them, in terms of production capacity specifications, the company said that China has manufacturing capacity and labor resources.
In terms of raw material supply, the domestic industrial chain has the ability to supply raw materials after exporting European kits last year.
The increase in production capacity mainly depends on the supply of labor and labor, but There is a time course for productivity improvement
.
The company will comprehensively consider the two factors of efficiency and risk, and rationally plan production-related arrangements
.
